ASAP3 Antikörper

Produktnummer ABIN401043

Produktdetails anti-ASAP3 Antikörper

Target: ASAP3 (ArfGAP with SH3 Domain, Ankyrin Repeat and PH Domain 3 (ASAP3))

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser ASAP3 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Spezifität: This antibody is directed against UPLC1/ASAP3 protein.

Kreuzreaktivität (Details): Species reactivity (expected):Mouse, Rat.
Species reactivity (tested):Human.

Aufreinigung: Affinity chromatography on Protein A

Immunogen: Recombinant human UPLC1/ASAP3 protein

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: ELISA: 1/1,000 - 1/5,000. Western Blot: 1/1000 - 1/10,000.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.10 mg/mL (by UV absorbance at 280 nm)

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2 containing 0.01 % (w/v) Sodium Azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: -20 °C

Details zu ASAP3

Target: ASAP3 (ArfGAP with SH3 Domain, Ankyrin Repeat and PH Domain 3 (ASAP3))

Andere Bezeichnung: DDEFL1 (ASAP3 Produkte)

Synonyme: DDEFL1 antikoerper, ddefl1 antikoerper, zgc:113885 antikoerper, ACAP4 antikoerper, CENTB6 antikoerper, UPLC1 antikoerper, 9430088F20Rik antikoerper, Ddefl1 antikoerper, Gm140 antikoerper, ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 antikoerper, development and differentiation enhancing factor-like 1 antikoerper, ASAP3 antikoerper, asap3 antikoerper, DDEFL1 antikoerper, Asap3 antikoerper

Hintergrund: UPLC1 (up-regulated in liver cancer 1), also named DDEFL1 (development and differentiation-enhancing factor-like 1) or ASAP3, is a member of the AZAP family of proteins. These proteins catalyze the hydrolysis of GTP bound to ADP-ribosylation factor (Arf) proteins, thereby causing Arf inactivation. For this reason, the ASAPs are generally called ArfGAPs. The activity of ArfGAPs is dependent on the presence of phosphoinositides and is implicated in cellular processes such as membrane trafficking and remodeling of the actin cytoskeleton. Both ASAP1 and ASAP3 have recently been implicated in the development of human cancers. Abnormal activity of ArfGAPs may lead to the alterations characteristic of malignant cells, such as the high rate of proliferation and invasion. More specifically, ASAP3 has been found to be up-regulated in 80 % of the hepatocellular carcinomas examined. Initial biochemical characterization reveals that ASAP3 shows class-specific GAP activity on Arf proteins, preferring Arf5 over Arf1 and Arf6.Synonyms: ACAP4, ANK repeat and PH domain-containing protein 3, ASAP3, Arf-GAP with SH3 domain, CENTB6, Development and differentiation-enhancing factor-like 1, Protein up-regulated in liver cancer 1, UPLC1

Gen-ID: 55616

NCBI Accession: NP_001137250

UniProt: Q8TDY4